@katie-keith.bsky.social
This brief notwithstanding, access to medication abortion remains at risk. The next test will be whether the Trump admin defends FDA's regulation of mifepristone on the merits - or takes other steps towards nationwide restrictions on medication abortion.
www.huffpost.com/entry/gop-la...
www.huffpost.com/entry/gop-la...
GOP Lays Groundwork To Restrict Abortion Pill With New Junk Science Report
Recent comments from Trump’s FDA commissioner, coupled with an anti-abortion study on mifepristone, are setting off alarm bells among reproductive rights groups.
www.huffpost.com
May 5, 2025 at 8:48 PM
This brief notwithstanding, access to medication abortion remains at risk. The next test will be whether the Trump admin defends FDA's regulation of mifepristone on the merits - or takes other steps towards nationwide restrictions on medication abortion.
www.huffpost.com/entry/gop-la...
www.huffpost.com/entry/gop-la...
The Trump admin maintains the Biden admin's arguments on venue, standing, and exhaustion. DOJ also disputes the states' "birthrate" theory - that states can sue over any policy that affects their potential future birthrate. More here for Health Affairs: www.healthaffairs.org/content/fore...
Awaiting The Trump Administration On Medication Abortion | Health Affairs Forefront
By May 5, 2025, the Trump administration will file its first brief in <i>Missouri v. Food</i> and Drug Administration, staking out a position in the case on whether it will continue to defend the Food and Drug Administration’s regulation of mifepristone.
www.healthaffairs.org
May 5, 2025 at 8:48 PM
The Trump admin maintains the Biden admin's arguments on venue, standing, and exhaustion. DOJ also disputes the states' "birthrate" theory - that states can sue over any policy that affects their potential future birthrate. More here for Health Affairs: www.healthaffairs.org/content/fore...
By May 5, the Trump administration must choose whether to defend the FDA in court - or not. If not, nationwide restrictions on medication abortion (a major priority for anti-choice advocates) may soon follow.
GOP Lays Groundwork To Restrict Abortion Pill With New Junk Science Report
Recent comments from Trump’s FDA commissioner, coupled with an anti-abortion study on mifepristone, are setting off alarm bells among reproductive rights groups.
www.huffpost.com
May 4, 2025 at 4:06 PM
By May 5, the Trump administration must choose whether to defend the FDA in court - or not. If not, nationwide restrictions on medication abortion (a major priority for anti-choice advocates) may soon follow.
Republican AGs in Missouri, Kansas, and Idaho are fighting to restrict mifepristone (a drug approved by FDA nearly 25 years ago that accounts for the majority of abortions in the U.S.) in every state. They want to reinstate restrictions that FDA rejected as unnecessary nearly a decade ago.
May 4, 2025 at 4:06 PM
Republican AGs in Missouri, Kansas, and Idaho are fighting to restrict mifepristone (a drug approved by FDA nearly 25 years ago that accounts for the majority of abortions in the U.S.) in every state. They want to reinstate restrictions that FDA rejected as unnecessary nearly a decade ago.
We won't know until it is issued. But, in theory, it could address how Section 1557 applies to Affordable Care Act marketplace plans or potentially CMS programs. But I don't think this will be a broader rule on 1557 because the OMB entry says this rule is from CMS, not the Office for Civil Rights.
February 12, 2025 at 7:34 PM
We won't know until it is issued. But, in theory, it could address how Section 1557 applies to Affordable Care Act marketplace plans or potentially CMS programs. But I don't think this will be a broader rule on 1557 because the OMB entry says this rule is from CMS, not the Office for Civil Rights.
This report - published just last month by Peter Nelson, the new head of CCIIO - could offer more clues about the Biden-era policies that the Trump admin might roll back. The report touches on essential health benefits, enrollment periods, and more.
files.americanexperiment.org/wp-content/u...
files.americanexperiment.org/wp-content/u...
files.americanexperiment.org
February 12, 2025 at 5:02 PM
This report - published just last month by Peter Nelson, the new head of CCIIO - could offer more clues about the Biden-era policies that the Trump admin might roll back. The report touches on essential health benefits, enrollment periods, and more.
files.americanexperiment.org/wp-content/u...
files.americanexperiment.org/wp-content/u...
It is anybody's guess what will be proposed. But the Trump-era rule from 2017 included policies that made it harder for consumers to enroll (shortening OEP, limiting SEPs, etc.) and deferred to states on key standards (e.g., network adequacy). More here: www.healthaffairs.org/content/fore...
Examining The Final Market Stabilization Rule: What's There, What's Not, And How Might It Work? (Updated) | Health Affairs Forefront
The Trump administration has issued a final market stabilization rule. Stabilizing the individual and small group markets is an important concern, as many counties will have only one insurer next year. Does the rule do what’s needed, and what threats to market stability does it leave unaddressed?
www.healthaffairs.org
February 12, 2025 at 5:02 PM
It is anybody's guess what will be proposed. But the Trump-era rule from 2017 included policies that made it harder for consumers to enroll (shortening OEP, limiting SEPs, etc.) and deferred to states on key standards (e.g., network adequacy). More here: www.healthaffairs.org/content/fore...